TWI358290B - Topical nepafenac formulations - Google Patents
Topical nepafenac formulations Download PDFInfo
- Publication number
- TWI358290B TWI358290B TW094141182A TW94141182A TWI358290B TW I358290 B TWI358290 B TW I358290B TW 094141182 A TW094141182 A TW 094141182A TW 94141182 A TW94141182 A TW 94141182A TW I358290 B TWI358290 B TW I358290B
- Authority
- TW
- Taiwan
- Prior art keywords
- composition
- group
- patent application
- carbomer
- preservative
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 35
- QEFAQIPZVLVERP-UHFFFAOYSA-N nepafenac Chemical compound NC(=O)CC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1N QEFAQIPZVLVERP-UHFFFAOYSA-N 0.000 title claims description 8
- 229960001002 nepafenac Drugs 0.000 title claims description 8
- 238000009472 formulation Methods 0.000 title 1
- 230000000699 topical effect Effects 0.000 title 1
- 229920002125 Sokalan® Polymers 0.000 claims description 10
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 8
- 229960001631 carbomer Drugs 0.000 claims description 6
- 239000002736 nonionic surfactant Substances 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical group O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 claims description 5
- 229960004224 tyloxapol Drugs 0.000 claims description 5
- 229920001664 tyloxapol Polymers 0.000 claims description 5
- RFIMISVNSAUMBU-UHFFFAOYSA-N 2-(hydroxymethyl)-2-(prop-2-enoxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC=C RFIMISVNSAUMBU-UHFFFAOYSA-N 0.000 claims description 4
- -1 propylene sucrose Chemical compound 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 239000003755 preservative agent Substances 0.000 claims 4
- 230000002335 preservative effect Effects 0.000 claims 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 3
- 229930195725 Mannitol Natural products 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- 239000002738 chelating agent Substances 0.000 claims 3
- 239000003153 chemical reaction reagent Substances 0.000 claims 3
- 239000000594 mannitol Substances 0.000 claims 3
- 235000010355 mannitol Nutrition 0.000 claims 3
- 230000003204 osmotic effect Effects 0.000 claims 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims 2
- 229960000686 benzalkonium chloride Drugs 0.000 claims 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical group [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 claims 2
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 claims 2
- 239000003002 pH adjusting agent Substances 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 239000004155 Chlorine dioxide Substances 0.000 claims 1
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 235000019398 chlorine dioxide Nutrition 0.000 claims 1
- 230000003750 conditioning effect Effects 0.000 claims 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims 1
- 238000002309 gasification Methods 0.000 claims 1
- 150000004820 halides Chemical class 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 1
- 229910052938 sodium sulfate Inorganic materials 0.000 claims 1
- 235000011152 sodium sulphate Nutrition 0.000 claims 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 claims 1
- 229960005066 trisodium edetate Drugs 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
第94141182號專利申諳案說明書暨申請專利範圍修正本修正曰期·· 100年丨丨月30曰 代表。、? 奈帕芬胺為一種已知化合物。可以數種已知方法製備 。請見’如’美國專利號5,475,034與4,313,949。本發明組 成物含有0.09-0.11%奈帕芬胺，較佳為〇1%奈帕芬胺。 除了奈帕芬胺之外，本發明之懸浮液組成物亦含有卡 波姆(carbomer) ’作為增稠劑或生理穩定性_增強劑。適用 於本發明之卡波姆(carbomer)亦已知為“羧基乙烯基聚合物 或缓基聚甲稀。為商業上可購得’如購自Noveon，Inc. (Cleveland，Ohi〇) ’ 此產品之商標名稱為 Carb〇p〇1®。Carb〇p〇1 聚合物為交聯性、含丙烯酸-聚合物。其係與丙烯基蔗糖或 烯丙基季戊四醇交聯。Carbopol聚合物為丙烯酸之聚合物， 經匸他川烷基丙烯酸酯修飾，並與烯丙基季戊四醇交聯。用 於本發明中之較佳卡波姆(carb〇mer)為與丙烯基蔗糖或烯 丙基季戊四醇交聯之丙烯酸聚合物，商品名稱為Carb〇p〇1® 974P。本發明組成物中卡波姆(carbomer)之濃度範圍通常為 0.4 — 0.6 %，較佳為〇 5 〇/〇。 本發明組成物亦含有眼科上可接受之非離子性界面活 性劑。許多眼科上可接受之非離子性界面活性劑為已知。 適用之非離子性界面活性劑包括，但不侷限於，泰洛沙伯 (tyloxapol);聚氧基乙烯基山梨醣酯，如聚山梨醣酯如聚 山梨醣酯60與聚山梨醣酯8〇 ;聚乙氧基化蓖麻油如 CremophorEL;聚乙氧基化氫化蓖麻油，如Hc〇 4〇以及 伯洛沙姆（P〇l〇xamers)。最佳之界面活性劑為泰洛沙伯 (tyloxapol)。若為泰洛沙伯（tyl〇xap〇1),該界面活性劑一般
Claims (1)
1358290 第94141182號專利申請案說明書暨申請專利範100年11月30曰 十、申請專利範圍:1^511 1. 一種可局部投藥之眼科用組成物，由下列組ik h a) 0.09-0.1i%(w/v)奈帕芬胺； b) 0_4 - 0.6% (w/v)卡波姆(carbomer); c) 一非離子性界面活性劑； d) —滲透強度-調整試劑，其量足以使該組成物具 250 - 350 mOsm/kg之渗透度； e) — pH-調整試劑，其量足以使該組成物具7.0-7.8 之pH值；以及 f) 水， 其中該組成物選擇性地包含一成份，選自於由防腐 劑與螯合劑組成之族群。 2. 如申請專利範圍第1項之組成物，其中該組成物含有 0.1% (w/v)奈帕芬胺。 3_如申請專利範圍第1項之組成物，其中該組成物含有 0.5% (w/v)卡波姆(carbomer)。 4. 如申請專利範圍第1項之組成物，其中該卡波姆 (carbomer)為一丙稀酸與稀丙基蔗糖或烯丙基季戊四醇 交聯之聚合物。 5. 如申請專利範圍第1項之組成物，其中該非離子性界面 活性劑為泰洛沙伯（tyloxapol)。 6. 如申請專利範圍第5項之組成物，其中該組成物包含 0.01% (w/v)泰洛沙伯’(tyloxapol)。 7. 如申請專利範圍第1項之組成物，其中該滲透強度-調整 13 1358290 第州侧2號專利申請案說明書暨申請專利範圍修正本修正 曰期：100年11月3〇 試劑係選自於由金屬氣化鹽與甘 8.如申請專利範圍第7項之組成物， 試劑包含氣化鈉與甘露醇。 曰 露醇組成之族群。 其中該滲透強度-調整 9.如申請專利範圍第8項之組成物，其中該組成物係包含 0‘3 - 0.5% (w/v)氯化鈉與2 _ 3% (w/v)甘露醇。 K)·如申請專職圍第9項之組成物，其中該组成物係包含 0.4% (w/ν)氯化鈉與2_4% (w/v)甘露醇。 11_如申請專利範圍第丨項之組成物，其#該pH調整試劑係 選自於由氫氣酸與氫氧化鈉組成之族群。 12·如申請專利·第丨項之組成物，其中肋成物之阳值 為 7·3 — 7·7。 13.如申請專利範圍第1項之組成物’其中該組成物含有防 腐劑與螫合劑二者。 14·如申請專利範圍第1項之組成物，其中該防腐劑係選自 於由鹵化苄二甲烴銨(benzaik〇nium halides);聚季銨鹽 -l(P〇lyquaternium-l);以及二氧化氯組成之族群。 15·如申請專利範圍第1項之組成物，其中該防腐劑為氣化 一 甲煙敍（benzalkonium chloride)。 16.如申請專利範圍第15項之組成物，其中該組成物包含 0.005%氣化苄二甲烴銨。 17.如申請專利範圍第1項之組成物，其令該螫合劑係選自 於由依地酸二鈉鹽；依地酸三鈉鹽；依地酸四鈉鹽；以 及二伸乙基胺五醋酸鹽（diethyleneamine pentaacetate)組 成之族群。 14 1358290 第94141182號專利申請案說明書暨申請專利範圍修正本修正日期：100年11月30曰 18. 如申請專利範圍第17項之組成物，其中該組成物包含 0.001 - 0.1% (w/v)依地酸二鈉鹽。 19. 如申請專利範圍第1項之組成物，用於治療一病患眼部 發炎病症。 20. —種可局部投藥之眼科用組成物，由下列組成 a) 0.1%(w/v)奈帕芬胺； b) 0.5% (w/v)卡波姆(carbomer); c) 0.01%(w/v)泰洛沙伯（tyloxapol); d) 0.4% (w/v)氣化鈉； e) 2.4%(w/v)甘露醇； f) 一pH-調整試劑，其量足以使該組成物具7.3 -7.7 之pH值； g) 0.0〇5% (w/v)氯化苄二曱烴銨； h) 0.01%依地酸二鈉；以及 i) 純水。 15
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63256204P | 2004-12-02 | 2004-12-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200626132A TW200626132A (en) | 2006-08-01 |
| TWI358290B true TWI358290B (en) | 2012-02-21 |
Family
ID=35848959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW094141182A TWI358290B (en) | 2004-12-02 | 2005-11-23 | Topical nepafenac formulations |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US7834059B2 (zh) |
| EP (1) | EP1819362B1 (zh) |
| JP (2) | JP4968844B2 (zh) |
| KR (1) | KR101289661B1 (zh) |
| CN (1) | CN101068573A (zh) |
| AR (1) | AR052252A1 (zh) |
| AT (1) | ATE476200T1 (zh) |
| AU (1) | AU2005311738B2 (zh) |
| BR (1) | BRPI0518904B1 (zh) |
| CA (1) | CA2586807C (zh) |
| CY (1) | CY1110780T1 (zh) |
| DE (1) | DE602005022756D1 (zh) |
| DK (1) | DK1819362T3 (zh) |
| ES (1) | ES2348249T3 (zh) |
| MX (1) | MX2007006558A (zh) |
| PL (1) | PL1819362T3 (zh) |
| PT (1) | PT1819362E (zh) |
| RU (1) | RU2007124638A (zh) |
| SI (1) | SI1819362T1 (zh) |
| TW (1) | TWI358290B (zh) |
| UY (1) | UY29238A1 (zh) |
| WO (1) | WO2006060618A2 (zh) |
| ZA (1) | ZA200704763B (zh) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI358290B (en) | 2004-12-02 | 2012-02-21 | Alcon Inc | Topical nepafenac formulations |
| WO2006121964A2 (en) * | 2005-05-10 | 2006-11-16 | Alcon, Inc. | Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders |
| PT1885336E (pt) * | 2005-05-10 | 2009-05-07 | Alcon Inc | Formulações de suspensão compreendendo um princípio activo, um tensoactivo poloxâmero ou meroxapol e um glicol, sua utilização no fabrico de um medicamento para tratamento de distúrbios oftálmicos |
| US20090010850A1 (en) * | 2007-05-24 | 2009-01-08 | Ousler Iii George W | Formulations and methods for treating dry eye |
| TW200812575A (en) * | 2006-04-28 | 2008-03-16 | Alcon Inc | Formulations containing amide derivatives of carboxylic acid NSAIDs for topical administration to the eye |
| US20080057022A1 (en) * | 2006-08-30 | 2008-03-06 | Erning Xia | Ophthalmic Pharmaceutical Compositions and Uses Thereof |
| TWI531362B (zh) * | 2008-07-21 | 2016-05-01 | 艾爾康股份有限公司 | 具有治療劑遞送能力之眼科裝置 |
| TW201023912A (en) | 2008-12-05 | 2010-07-01 | Alcon Res Ltd | Pharmaceutical suspension |
| AU2010221438C1 (en) * | 2009-03-03 | 2015-01-29 | Alcon Research, Ltd. | Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye |
| WO2010101989A1 (en) * | 2009-03-03 | 2010-09-10 | Alcon Research, Ltd. | PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
| PT2506831E (pt) | 2009-12-03 | 2014-01-08 | Alcon Res Ltd | Suspensões de nanopartículas contendo um polímero de carboxivinilo |
| US9544143B2 (en) | 2010-03-03 | 2017-01-10 | Duo Security, Inc. | System and method of notifying mobile devices to complete transactions |
| US9532222B2 (en) | 2010-03-03 | 2016-12-27 | Duo Security, Inc. | System and method of notifying mobile devices to complete transactions after additional agent verification |
| US9467463B2 (en) | 2011-09-02 | 2016-10-11 | Duo Security, Inc. | System and method for assessing vulnerability of a mobile device |
| RU2014129268A (ru) * | 2011-12-16 | 2016-02-10 | Аллерган, Инк. | Офтальмологические составы, которые содержат привитые сополимеры поливинилкапролактам-поливинилацетат-полиэтиленгликоля |
| EP3013790A1 (en) | 2013-06-27 | 2016-05-04 | Mylan Laboratories Ltd. | Process for the preparation of nepafenac |
| CN104490861A (zh) * | 2014-11-21 | 2015-04-08 | 三明欣茂药业有限公司 | 一种缓释型奈帕芬胺眼用制剂 |
| PT3721868T (pt) | 2015-01-26 | 2022-08-12 | Bausch & Lomb | Composição para suspensão oftálmica |
| US9930060B2 (en) | 2015-06-01 | 2018-03-27 | Duo Security, Inc. | Method for enforcing endpoint health standards |
| CN107024550A (zh) * | 2016-12-21 | 2017-08-08 | 广州仁恒医药科技股份有限公司 | 奈帕芬胺眼用药物组合物的质控方法 |
| CN106963730A (zh) * | 2016-12-22 | 2017-07-21 | 广州仁恒医药科技股份有限公司 | 高度稳定的奈帕芬胺眼用药物组合物 |
| US10412113B2 (en) | 2017-12-08 | 2019-09-10 | Duo Security, Inc. | Systems and methods for intelligently configuring computer security |
| US11658962B2 (en) | 2018-12-07 | 2023-05-23 | Cisco Technology, Inc. | Systems and methods of push-based verification of a transaction |
| IT201900000561A1 (it) * | 2019-01-14 | 2020-07-14 | Medivis S R L | Formulazioni topiche oftalmiche chimicamente e fisicamente stabili a base di Nepafenac |
| JP6994061B2 (ja) * | 2019-02-15 | 2022-01-14 | ノバルティス アーゲー | ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤 |
| CN114272207B (zh) * | 2022-01-21 | 2023-04-11 | 山东诺明康药物研究院有限公司 | 一种纳米晶混悬滴眼液及其制备方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1226344A (zh) * | 1967-07-31 | 1971-03-24 | ||
| SE400966B (sv) * | 1975-08-13 | 1978-04-17 | Robins Co Inc A H | Forfarande for framstellning av 2-amino-3-(eller 5-)bensoyl-fenylettiksyror |
| US4313949A (en) * | 1979-09-26 | 1982-02-02 | A. H. Robins Company, Inc. | Method of producing an inhibitory effect on blood platelet aggregation |
| US4254146A (en) * | 1979-10-18 | 1981-03-03 | A. H. Robins Company, Inc. | 3-Benzoyl-2-nitrophenylacetic acids, metal salts, amides and esters |
| IL61945A (en) | 1980-02-19 | 1984-09-30 | Robins Co Inc A H | 2-amino-3-(hydroxy(phenyl)methyl)phenylacetic acids,esters and amides and pharmaceutical compositions containing them |
| US4503073A (en) * | 1981-01-07 | 1985-03-05 | A. H. Robins Company, Incorporated | 2-Amino-3-(alkylthiobenzoyl)-phenylacetic acids |
| IL64724A0 (en) | 1981-02-17 | 1982-03-31 | Robins Co Inc A H | 2-amino-3-(halobenzoyl)-methylphenylacetic acids and esters and salts thereof and pharmaceutical compositions containing them |
| US4568695A (en) * | 1983-12-07 | 1986-02-04 | A. H. Robins Company, Incorporated | 2-Amino-3-benzoyl-phenethylalcohols and intermediates therefor |
| EP0195582B1 (en) * | 1985-03-14 | 1990-01-24 | SMITH KLINE DAUELSBERG GmbH | 5-aminosalicylic acid derivatives of non-steroidal antiinflammatory acids |
| US4851443A (en) * | 1985-03-14 | 1989-07-25 | Smith Kline Dauelsberg, Gmbh | Carboxylic acid amides, compositions and medical use thereof |
| US4683242A (en) * | 1985-10-28 | 1987-07-28 | A. H. Robins Company, Incorporated | Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters |
| DK406686D0 (da) * | 1986-08-26 | 1986-08-26 | Hans Bundgaard | Carboxylsyrederivater |
| CA1325382C (en) * | 1988-01-27 | 1993-12-21 | Takahiro Ogawa | Locally administrable therapeutic composition for inflammatory disease |
| US5521222A (en) * | 1989-09-28 | 1996-05-28 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
| US5461081A (en) * | 1989-09-28 | 1995-10-24 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
| US5624893A (en) * | 1993-10-14 | 1997-04-29 | Alcon Laboratories, Inc. | Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation |
| US5475034A (en) | 1994-06-06 | 1995-12-12 | Alcon Laboratories, Inc. | Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders |
| US6066671A (en) * | 1997-12-19 | 2000-05-23 | Alcon Laboratories, Inc. | Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides |
| AR030345A1 (es) * | 2000-08-14 | 2003-08-20 | Alcon Inc | Metodo de tratamiento de desordenes relacionados con angiogenesis |
| AR030346A1 (es) * | 2000-08-14 | 2003-08-20 | Alcon Inc | Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico |
| CA2483275A1 (en) * | 2002-05-03 | 2003-11-13 | Alcon, Inc. | Method of treating vascular endothelial growth factor mediated vascular disorders using amfenac or nepafenac |
| US8129431B2 (en) * | 2003-01-21 | 2012-03-06 | Senju Pharmaceutical Co., Ltd. | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
| TWI358290B (en) | 2004-12-02 | 2012-02-21 | Alcon Inc | Topical nepafenac formulations |
-
2005
- 2005-11-23 TW TW094141182A patent/TWI358290B/zh active
- 2005-11-28 AR ARP050104964A patent/AR052252A1/es not_active Application Discontinuation
- 2005-11-29 UY UY29238A patent/UY29238A1/es not_active Application Discontinuation
- 2005-12-02 EP EP05825662A patent/EP1819362B1/en not_active Expired - Lifetime
- 2005-12-02 BR BRPI0518904-7A patent/BRPI0518904B1/pt active IP Right Grant
- 2005-12-02 PL PL05825662T patent/PL1819362T3/pl unknown
- 2005-12-02 CA CA2586807A patent/CA2586807C/en not_active Expired - Lifetime
- 2005-12-02 MX MX2007006558A patent/MX2007006558A/es active IP Right Grant
- 2005-12-02 JP JP2007544521A patent/JP4968844B2/ja not_active Expired - Lifetime
- 2005-12-02 WO PCT/US2005/043545 patent/WO2006060618A2/en not_active Ceased
- 2005-12-02 AU AU2005311738A patent/AU2005311738B2/en not_active Expired
- 2005-12-02 AT AT05825662T patent/ATE476200T1/de active
- 2005-12-02 DK DK05825662.9T patent/DK1819362T3/da active
- 2005-12-02 PT PT05825662T patent/PT1819362E/pt unknown
- 2005-12-02 US US11/292,484 patent/US7834059B2/en active Active
- 2005-12-02 KR KR1020077012413A patent/KR101289661B1/ko not_active Expired - Fee Related
- 2005-12-02 ZA ZA200704763A patent/ZA200704763B/xx unknown
- 2005-12-02 SI SI200531107T patent/SI1819362T1/sl unknown
- 2005-12-02 CN CNA200580041442XA patent/CN101068573A/zh active Pending
- 2005-12-02 RU RU2007124638/15A patent/RU2007124638A/ru unknown
- 2005-12-02 DE DE602005022756T patent/DE602005022756D1/de not_active Expired - Lifetime
- 2005-12-02 ES ES05825662T patent/ES2348249T3/es not_active Expired - Lifetime
-
2010
- 2010-09-14 CY CY20101100830T patent/CY1110780T1/el unknown
- 2010-09-23 US US12/888,631 patent/US8071648B2/en not_active Expired - Lifetime
-
2011
- 2011-10-05 US US13/253,648 patent/US8324281B2/en not_active Expired - Lifetime
- 2011-11-25 JP JP2011257966A patent/JP2012041368A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI358290B (en) | Topical nepafenac formulations | |
| ES2542728T3 (es) | Composiciones farmacéuticas que tienen la biodisponibilidad deseable | |
| DE3872029T2 (de) | Rektal absorbierbare form von l-dopa. | |
| JP3689123B2 (ja) | ビタミンａ類可溶化水性点眼剤 | |
| RU2009149687A (ru) | Фармацевтические композиции и способы лечения сухих кератитов | |
| JP2009102291A (ja) | チモロール、ドルゾラミドおよびブリモニジンからなる薬学的に安定な化合物 | |
| JP2009102291A6 (ja) | チモロール、ドルゾラミドおよびブリモニジンからなる薬学的に安定な化合物 | |
| JP2003206241A (ja) | 眼科用剤 | |
| JP2009161454A (ja) | 眼科用組成物 | |
| US20060257486A1 (en) | Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders | |
| JP4355574B2 (ja) | 点眼剤 | |
| JP5132015B2 (ja) | 点眼剤組成物 | |
| WO2007007894A1 (ja) | キサンタンガムおよびテルペノイドを含有する点眼剤 | |
| JP2015067607A (ja) | 複数の成分を配合した点眼剤 | |
| JP2007169232A (ja) | 眼科用組成物 | |
| JP2004059479A (ja) | 点眼剤組成物 | |
| WO2013047373A1 (ja) | 亜塩素酸塩を含有する水性製剤 | |
| HK1104225B (zh) | 外用奈帕芬胺的公式表述 | |
| JP2001139493A (ja) | 人工涙液型点眼剤組成物 | |
| JP2010265326A (ja) | 眼科用組成物 | |
| JPWO2011096513A1 (ja) | 点眼剤 | |
| JP2008110981A (ja) | 点眼剤 |